BeiGene prsentiert innovatives Hmatologie-Portfolio fr maligne B-Zell-Erkrankungen bei ASH 2024
BGNE Stock | USD 187.50 20.12 9.69% |
About 70% of BeiGene's investor base is looking to short. The analysis of the overall investor sentiment regarding BeiGene suggests that many traders are alarmed. The current market sentiment, together with BeiGene's historical and current headlines, can help investors time the market. In addition, many technical investors use BeiGene stock news signals to limit their universe of possible portfolio assets.
BeiGene |
BeiGene, Ltd. , ein globales Onkologieunternehmen, gab heute bekannt, dass es bei der 66. Jahresversammlung un
Read at businesswire.com
BeiGene Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BeiGene can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BeiGene Fundamental Analysis
We analyze BeiGene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BeiGene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BeiGene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
BeiGene is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
BeiGene Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BeiGene stock to make a market-neutral strategy. Peer analysis of BeiGene could also be used in its relative valuation, which is a method of valuing BeiGene by comparing valuation metrics with similar companies.
Peers
BeiGene Related Equities
IMAB | I Mab | 0.95 | ||||
BPMC | Blueprint Medicines | 0.87 | ||||
INCY | Incyte | 0.36 | ||||
IMVT | Immunovant | 0.28 | ||||
TVTX | Travere Therapeutics | 0.11 | ||||
KRYS | Krystal Biotech | 0.31 | ||||
BMRN | Biomarin Pharmaceutical | 0.96 | ||||
APLS | Apellis Pharmaceuticals | 1.09 | ||||
IONS | Ionis Pharmaceuticals | 1.10 | ||||
AKRO | Akero Therapeutics | 1.54 | ||||
PCVX | Vaxcyte | 1.77 | ||||
ASND | Ascendis Pharma | 2.08 | ||||
ARWR | Arrowhead Pharmaceuticals | 3.26 | ||||
LEGN | Legend Biotech | 8.96 |
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |